285 related articles for article (PubMed ID: 25804233)
21. [The role of biochemical markers with special regard to troponin, CK-MB, NT-proBNP as early biomarkers of cardiotoxicity among women after chemotherapy due to breast cancer].
Stachowiak P; Milchert-Leszczyńska M; Falco M; Polakowska M; Wojtarowicz A; Kaliszczak R; Safranow K; Kornacewicz-Jach Z
Przegl Lek; 2016; 73(6):359-63. PubMed ID: 29668198
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab.
Knobloch K; Tepe J; Lichtinghagen R; Luck HJ; Vogt PM
Int J Cardiol; 2008 Mar; 125(1):113-5. PubMed ID: 17400308
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
24. Can we predict clinical cardiotoxicity with cardiac biomarkers in patients after haematopoietic stem cell transplantation?
Roziakova L; Mistrik M; Batorova A; Kruzliak P; Bojtarova E; Dubrava J; Gergel J; Mladosievicova B
Cardiovasc Toxicol; 2015 Jul; 15(3):210-6. PubMed ID: 25287586
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.
Putt M; Hahn VS; Januzzi JL; Sawaya H; Sebag IA; Plana JC; Picard MH; Carver JR; Halpern EF; Kuter I; Passeri J; Cohen V; Banchs J; Martin RP; Gerszten RE; Scherrer-Crosbie M; Ky B
Clin Chem; 2015 Sep; 61(9):1164-72. PubMed ID: 26220066
[TBL] [Abstract][Full Text] [Related]
26. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.
Cao L; Hu WG; Kirova YM; Yang ZZ; Cai G; Yu XL; Ma JL; Guo XM; Shao ZM; Chen JY
Cancer Radiother; 2014 Mar; 18(2):119-24. PubMed ID: 24642505
[TBL] [Abstract][Full Text] [Related]
27. [Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab].
Pistillucci G; Ciorra AA; Sciacca V; Raponi M; Rossi R; Veltri E
Clin Ter; 2015; 166(1):e67-71. PubMed ID: 25756270
[TBL] [Abstract][Full Text] [Related]
28. Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: a prospective study.
Piotrowski G; Gawor R; Bourge RC; Stasiak A; Potemski P; Gawor Z; Nanda NC; Banach M
Pharmacol Res; 2013 Dec; 78():41-8. PubMed ID: 24171840
[TBL] [Abstract][Full Text] [Related]
29. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
30. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
31. Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients.
Marinko T; Stojanov Konda JT; Dolžan V; Goričar K
Dis Markers; 2020; 2020():6645588. PubMed ID: 33425072
[TBL] [Abstract][Full Text] [Related]
32. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
[TBL] [Abstract][Full Text] [Related]
33. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
[TBL] [Abstract][Full Text] [Related]
34. [Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure].
Pokorná V; Jurkovicová O; Kaluzay J; Stecová A; Pont'uch P
Vnitr Lek; 2010 Aug; 56(8):788-94. PubMed ID: 20845610
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P;
J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778
[TBL] [Abstract][Full Text] [Related]
37. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.
Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Cohen V; Gosavi S; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
Am J Cardiol; 2011 May; 107(9):1375-80. PubMed ID: 21371685
[TBL] [Abstract][Full Text] [Related]
38. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
39. Plasma N-terminal pro-B-type natriuretic peptide as a predictor of perioperative and long-term outcome after vascular surgery.
Schouten O; Hoeks SE; Goei D; Bax JJ; Verhagen HJ; Poldermans D
J Vasc Surg; 2009 Feb; 49(2):435-41; discussion 441-2. PubMed ID: 19028043
[TBL] [Abstract][Full Text] [Related]
40. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
